TOMÍŠKOVÁ, Marcela, Jana SKŘIČKOVÁ, B. ROBEŠOVÁ, M. BAJEROVÁ, Dana DVOŘÁKOVÁ, Jitka HAUSNEROVÁ and Mojmír MOULIS. Activating mutations in the epidermal growth factor receptor gene in non-small cell lung cancer fixed tissue: Analysis and one center experience. In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. doi:10.1016/j.lungcan.2012.05.080.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Activating mutations in the epidermal growth factor receptor gene in non-small cell lung cancer fixed tissue: Analysis and one center experience
Name in Czech Aktivace mutací v receptoru genu epidermálního růstového faktoru u NSCLC: Zkušenost jednoho centra
Authors TOMÍŠKOVÁ, Marcela (203 Czech Republic, guarantor, belonging to the institution), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), B. ROBEŠOVÁ (203 Czech Republic), M. BAJEROVÁ (203 Czech Republic), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution) and Mojmír MOULIS (203 Czech Republic, belonging to the institution).
Edition 13th Central European Lung Cancer Conference, 2012.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.392
RIV identification code RIV/00216224:14110/12:00060613
Organization unit Faculty of Medicine
ISSN 0169-5002
Doi http://dx.doi.org/10.1016/j.lungcan.2012.05.080
UT WoS 000305842300081
Keywords (in Czech) bronchogenní karcinom; erlotinib
Keywords in English lung cancer; erlotinib
Changed by Changed by: prof. MUDr. Jana Skřičková, CSc., učo 1808. Changed: 14. 2. 2013 15:11.
Abstract
Targeted treatment of patients with non small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI) of epidermal growth factor receptor gene (EGFR) is conditioned by EGFR mutation status assessment. Tyrosine kinase domains of exons 18–21 of gene EGFR was analysed in non selected NSCLC patients.
Abstract (in Czech)
Cílená léčba nemocných s nemalobuněčným bronchogenním karcinomem (NSCLC) inhibitory tyrosin kinázy (TKI) receptorového genu epidermalního růstového faktoru EGFR) je podmíněans hodnocením matačního statusu EGFR.Byly analyzovány tyrosinkinázové domény exonů 18–21 genu EGFR u neselektovaných NSCLC pacientů.
PrintDisplayed: 27. 5. 2022 06:10